New royalty-based investment model (IMAGE)
Caption
ALS — also often called Lou Gehrig’s disease — is a progressive, neurodegenerative disease with no cure. Despite its devastating impact, the pace of new therapy development has remained sluggish — largely due to the high cost, duration, and risks associated with traditional clinical trials. This bottleneck has often discouraged conventional investors, leaving promising research to languish. To tackle this challenge, researchers propose an investment fund that finances half the cost of an adaptive platform trial in exchange for future royalties from successful drugs that emerge from the trial.
Credit
MIT Sloan School of Management
Usage Restrictions
Credit: MIT Sloan School of Management
License
Original content